1 participants
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2023-12-05
- Start Date:
- 2021-05-05
- Completion:
- 2021-07-28
Conditions
- Recurrent Lymphoproliferative Disorder
- Refractory Lymphoproliferative Disorder
Interventions
- DRUG